This bill amends existing New Jersey law to establish an exemption from pharmacist licensing requirements for drug manufacturers and wholesale drug distributors involved in the distribution of dialysate drugs and devices for home dialysis in patients with end-stage renal disease. Specifically, the bill stipulates that these entities are not subject to the licensing requirements as long as they meet certain criteria, including that the drugs and devices are FDA-approved, properly registered, delivered in original sealed packaging, and only distributed upon a physician's order. Additionally, the delivery must be made directly to patients or healthcare providers for administration.

The bill also mandates that the manufacturer must contract with a registered consultant pharmacist to conduct weekly quality assurance assessments of the storage and distribution of the dialysis drugs and devices. This ensures that while the licensing requirement is waived, there is still oversight to maintain safety and compliance in the distribution process. The act is set to take effect on the first day of the third month following its enactment.

Statutes affected:
Introduced: 45:14-49